Skip to main content
Thyrogen® (thyrotropin alfa) for injection logo
A women driving her car

Thyrogen® (thyrotropin alfa) for injection, for intramuscular use allows your patients to continue taking their thyroid hormone medication and helps avoid some of the signs and symptoms of acute hypothyroidism


Indications and Usage

Thyrogen® (thyrotropin alfa) for injection, for intramuscular use

INDICATIONS AND USAGE

Thyrogen® (thyrotropin alfa) is a thyroid stimulating hormone indicated for:

Adjunctive Diagnostic Tool for Well-Differentiated Thyroid Cancer: Use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy.

Limitations of Use: 

  • Thyrogen-stimulated Tg levels are generally lower than, and do not correlate with Tg levels after thyroid hormone withdrawal.
  • Even when Thyrogen-Tg testing is performed in combination with radioiodine imaging, there remains a risk of missing a diagnosis of thyroid cancer or underestimating the extent of the disease.
  • Anti-Tg Antibodies may confound the Tg assay and render Tg levels uninterpretable.

Adjunct for Thyroid Remnant Ablation in Well-Differentiated Thyroid Cancer: Use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer.

Limitations of Use: 

  • The effect of Thyrogen on thyroid cancer recurrence greater than 5 years post-remnant ablation has not been evaluated.

The Uses of Thyrogen

Two women in a doctor's office, one a healthcare professional and the other a patient, engaged in conversation.

Thyrogen allows your patients to stay on their hormone replacement medication during ablation


Learn how thyroid hormone withdrawal can cause acute hypothyroidism.

A smiling couple seated at a table.

Thyrogen allows your patient to stay on their hormone replacement therapy during their diagnostic testing


Understand how Thyrogen may help patients during diagnostic testing.

 RAI selection protocol flowchart

Learn more about the use of Thyrogen in risk stratification and selection of patients for radioactive iodine ablation


Sanofi provides various services to help patients access Thyrogen.

Photos are not of actual patients.

Choose how to get Thyrogen® (thyrotropin alfa) for injection for your patients

Not sure which one to choose? Contact ThyrogenONE® for assistance

Desktop screen icon

Option 1: Sign up or log into the ThyrogenONE portal

The ThyrogenONE portal provides your office online access to help you and your patients:

  • Submit and track benefit verifications
  • Coordinate orders
  • Generate automatic alerts
Mobile screen icon

Option 2: Call ThyrogenONE at 1-88-THYROGEN (1-888-497-6436)

Dedicated ThyrogenONE Case Managers can assist you and your patients with the following:

  • Benefits Verification
  • Information on Ordering
  • Information on specialty pharmacy fulfillment

Access and Reimbursement Support

Thyrogen billing and coding guide

Billing and Coding Guide

Thyrogen prescription form

Thyrogen Prescription Form

Reimbursement Resources Available to Your Patients

Thyrogen co-pay assistant program application form

Thyrogen Co-Pay Self Application Form

Thyrogen patient assistance program application form

Thyrogen Patient Assistance Program Application Form

The Impact Of Thyrogen: Watch Videos on Patient and Doctor Perspectives

Important Safety InformationFull Prescribing Information

Impact of Thyrogen versus Thyroid Hormone Withdrawal (THW) – A Patient’s Story

Watch Amy, a thyroid cancer patient, explain how Thyrogen (thyrotropin alfa) helps alleviate some of the signs and symptoms of hypothyroidism caused by thyroid hormone withdrawal (THW).

Important Safety InformationFull Prescribing Information

The Benefits of Thyrogen versus Thyroid Hormone Withdrawal (THW) – A Doctor’s Perspective

Watch Dr. Stephanie Lee, MD, PhD, Associate Chief, Section of Endocrinology, Nutrition and Diabetes of Boston Medical Center, share her perspective on how Thyrogen (thyrotropin alfa) helps thyroid cancer patients in preparation for radioactive iodine (RAI) ablation treatment and monitoring for progression.

OTHER RESOURCES

   

Important Safety Information

Contraindications

If Thyrogen is administered with radioiodine, the contraindications to radioiodine also apply to this combination regimen. Refer to the radioiodine prescribing information for a list of contraindications for radioiodine.

Warnings and Precautions

Thyrogen-Induced Hyperthyroidism:

  • There have been reports of death in non-thyroidectomized patients and in patients with distant metastatic thyroid cancer in which events leading to death occurred within 24 hours after administration of Thyrogen. Caution should be exercised in patients who have substantial thyroid tissue still in situ or functional thyroid cancer metastases, specifically in the elderly and those with a known history of heart disease.
  • Hospitalization for administration of Thyrogen and post-administration observation in patients at risk should be considered.

Stroke:

  • There are post marketing reports of stroke in young women with risk factors for stroke, and neurological findings suggestive of stroke (e.g., unilateral weakness) occurring within 72 hours of Thyrogen administration in patients without known central nervous system metastases. The relationship between Thyrogen administration and stroke is unknown. Patients should be well-hydrated prior to treatment with Thyrogen.

Sudden Rapid Tumor Enlargement: 

  • Sudden, rapid and painful enlargement of residual thyroid tissue or distant metastases can occur following treatment with Thyrogen. Pretreatment with glucocorticoids should be considered for patients in whom tumor expansion may compromise vital anatomic structures.

Risks Associated with Radioiodine Treatment: 

  • If Thyrogen is administered with radioiodine (RAI), the warnings and precautions for RAI apply to this combination regimen. Refer to the RAI prescribing information for a full list of the warnings and precautions for RAI.

Adverse Reactions

The most common adverse reactions reported in clinical trials were nausea and headache.

Use in Specific Populations

Pregnancy:

  • If Thyrogen is administered with radioiodine, the combination regimen is contraindicated in pregnant women.
  • Available data with Thyrogen use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.

Lactation:

  • The concomitant use of Thyrogen and radioiodine (RAI) is contraindicated in lactating women. If Thyrogen is administered with RAI for diagnostic use, discontinue breastfeeding after RAI administration because of the potential for serious adverse reactions from RAI in the breastfed infant.
  • If Thyrogen is not administered with RAI, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Thyrogen and any potential adverse effects on the breastfed child. There are no available data on the presence of thyrotropin alfa in human milk, the effects on the breastfed infant, or the effects on milk production.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

Geriatric Use: Results from controlled trials do not indicate a difference in the safety and efficacy of Thyrogen between adult patients less than 65 years and those over 65 years of age.

Renal Impairment: Elimination of Thyrogen is significantly slower in dialysis-dependent end stage renal disease patients, resulting in prolonged elevation of TSH levels.

Indications

Thyrogen® (thyrotropin alfa) is a thyroid stimulating hormone indicated for:

Adjunctive Diagnostic Tool for Well-Differentiated Thyroid Cancer: Use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy.

Limitations of Use: 

  • Thyrogen-stimulated Tg levels are generally lower than, and do not correlate with Tg levels after thyroid hormone withdrawal.
  • Even when Thyrogen-Tg testing is performed in combination with radioiodine imaging, there remains a risk of missing a diagnosis of thyroid cancer or underestimating the extent of the disease.
  • Anti-Tg Antibodies may confound the Tg assay and render Tg levels uninterpretable.

Adjunct for Thyroid Remnant Ablation in Well-Differentiated Thyroid Cancer: Use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer.

Limitations of Use: 

  • The effect of Thyrogen on thyroid cancer recurrence greater than 5 years post-remnant ablation has not been evaluated.

Important Safety Information

Indications

Thyrogen, ThyrogenONE, and Sanofi are registered trademarks of Sanofi or an affiliate. All other trademarks mentioned above are the property of their respective owners. MAT-US-2017295-v4.0-03/2025